ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of ChromaDex (NASDAQ:CDXC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 9.09% over the past year to ($0.10), which missed the estimate of ($0.09).

Recap: ChromaDex Q4 Earnings

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2020 financial results. Fourth Quarter 2020 and Recent Highlights Total net sales of $15.4 million, up 18% from $13.1 million in the year ago quarter. Tru Niagen® net sales of $12.3 million, a 21% increase from the year ago quarter. Gross margin of 61.0%, a 400 basis point increase from the year ago quarter. Net loss was ($6.1) million or ($0.10) per share, an improvement of $0.05 per share y

ChromaDex Corporation Reports 2020 Financial Results

The stock price of Chromadex Corp (Nasdaq: CDXC) is trading at above 20% pre-market. This is why it happened.

CDXC Stock Price Increases Over 20% Pre-Market: Why It Happened

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000 Walmart retail stores across the United States beginning June 2021. ChromaDex will introduce Tru Niagen® in two packaging options for Walmart customers, which will have distinct serving sizes and price points. In addition to in-store availability, these two options will be available online with same-day delivery and in

ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States

On Wednesday, March 10, ChromaDex (NASDAQ:CDXC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

Earnings Preview: ChromaDex

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #HealthyAging--ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021 at 3:50pm ET (12:50pm PT). A webcast of the presentation will be posted under the investor relations section of ChromaDex's website at www.chromadex.com. A replay of the presentation will be available following the event. Management will also be participating in virtual one-on-one meetings on March 16

ChromaDex to Present at Oppenheimer 31st Annual Healthcare Conference

ChromaDex (CDXC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ChromaDex (CDXC) Surges 12%: Is This an Indication of Further Gains?

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and former director of Yale University's Yale-Griffin Prevention Research Center and past president of the American College of Lifestyle Medicine, to its Scientific Advisory Board (SAB). Dr. Katz is a leading expert in nutrition, health promotion and the prevention of chronic disease through his work as a researcher, author and cl

ChromaDex Appoints Preventative Medicine Specialist Dr. David L. Katz to its Scientific Advisory Board

ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

The stock price of ChromaDex Corp. (NASDAQ: CDXC) increased by 92.4% on Thursday, February 25. This is why it happened.

CDX Stock Price Increased 92.4%: Why It Happened

Chromadex Corp (NASDAQ: CDXC) shares jumped 111% in the regular and after-hours sessions today. What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 million.

Why ChromaDex Shares Spiked 111% Today

Promising Phase III clinical results for Covid-19 treatment have investors falling over themselves to buy into ChromaDex stock. The post CDXC Stock: Why ChromaDex Shares Are Rocketing Higher Today appeared first on InvestorPlace.

CDXC Stock: Why ChromaDex Shares Are Rocketing Higher Today

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the proto

New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients

The stock price of Chromadex Corp (NASDAQ: CDXC) increased by 15.64%. This is why it happened.

CDXC Stock Price Increased 15.64%: Why It Happened

ChromaDex Corp (NASDAQ: CDXC) enters into a securities purchase agreement to sell $25 million in common stock via a private placement led by a new international investor. The company will sell around 3.8 million shares at $6.50 per share, representing a discount of 22% on the last close price of $8.31 on Friday.

ChromaDex Raises $25M Via Equity At 22% Discount

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its common stock in a private placement. The private placement was led by a new international investor and is expected to close on or about February 23, 2021, subject to the satisfaction of customary closing conditions. In connection with the investment, the Company agreed to sell 3,846,153 shares of its common stock at a per shar

ChromaDex Announces $25 Million Private Placement of Common Stock

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial results for the fourth quarter ended December 31, 2020. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the fourth quarter resul

ChromaDex to Report Fourth Quarter 2020 Financial Results on Wednesday, March 10, 2021

ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

This Bioscience Company Is Trying To Defy The Aging Process

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a preprint publication website for papers under review by Cell Press Journals. The Phase 2 study reported a reduction in liver fat and inflammatory markers in patients with non-alcoholic fatty liver disease (NAFLD) when receiving a nutritional protocol inclu

New Study Results Finds Nutritional Protocol Including Nicotinamide Riboside Reduces Liver Fat and Improves Liver Function

ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

ChromaDex (CDXC) in Focus: Stock Moves 5.6% Higher

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating its potential to increase milk production among preterm mothers. This new human trial follows promising preclinical results which showed NR supplementation benefited both mother and newborn animals. The double-blinded study will compare mothers' levels of milk production and other markers of metabolism between the experiment

ChromaDex Announces New Clinical Trial to Investigate Niagen® and Milk Production Among Mothers in the Neonatal Intensive Care Unit (NICU)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online and in all Watsons Hong Kong stores. TRU NIAGEN® has been the #1 selling supplement in Watsons Hong Kong, and TRU NIAGEN® EX offers an alternative delivery method for the well-studied healthy aging vitamin, available to mix with one's favorite beverage or sports drink. “The health-oriented customers at Watsons have made TRU N

ChromaDex and Watsons Launch New TRU NIAGEN® EX Stick Packs in Hong Kong, Expanding Product Line and Advancing Global Retail Partnership

Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.

Chromadex: The Little Company That Could

ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales of $14.2 million, up 18% from $12.1 million from the year ago quarter. Tru Niagen® net sales of $11.9 million, a 22% increase from the year ago quarter. Net loss was ($4.2) million or ($0.07) per share, an improvement of $0.05 per share year-over-year. Adjusted EBITDA excluding total legal expense, a non-GAAP measure, was a loss of

News for ChromaDex Stock (CDXC)